Lupin gets tentative USFDA approval for Dolutegravir, Rilpivirine tablets

Image
Capital Market
Last Updated : Jan 16 2023 | 4:50 PM IST

The drug major said that it has received tentative approval from United States Food and Drug Administration (USFDA) to market its abbreviated new drug application (ANDA), Dolutegravir and Rilpivirine tablets, 50 mg/25 mg.

The approved ANDA is generic of Juluca tablets, 50 mg/25 mg of ViiV Healthcare Company.

Dolutegravir and Rilpivirine helps to decrease the amount of HIV in the blood and increase the number of immune cells that help to fight infections in your body.

Dolutegravir and Rilpivirine tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of $666 million in the U.S. (IQVIA MAT September 2022).

Separately Lupin said that USFDA inspected the company's Somerset, New Jersey, U.S.A. manufacturing facility from 2 January to 13 January 2023 and issued a form-483 with two observations.

"We are addressing the observations comprehensively and will work with the U.S. FDA to resolve these issues at the earliest. We uphold quality and compliance with utmost importance and are committed to be compliant with CGMP standards across all our facilities," the drug major said.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

On consolidated basis the company reported net profit of Rs 129.73 crore in Q2 FY23 as against net loss of Rs 2098.04 crore in Q2 FY22. Revenue from operations rose 2.2% to Rs 4091.16 crore in Q2 FY23 as compared to Rs 4003.42 crore in Q2 FY22.

The scrip was down 0.24% to Rs 753.75 on the BSE.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 16 2023 | 2:51 PM IST

Next Story